Mutations of KRAS and BRAF are mutually exclusive in pancreatic cancers, which suggest that the activating mutations of these genes can compensate for each other in pancreatic cancer phenotypes (7). This evidence concerns the gene BRAF and familial pancreatic carcinoma.